Trevena Announces Publication of TRV130 Phase 2 Bunionectomy Data in the Journal PAIN®

Trevena, Inc. TRVN, a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), today announced the publication of the full results from its Phase 2a/b trial of TRV130 in postoperative pain following bunionectomy surgery in the online edition of PAIN®, the Journal of the International Association for the Study of Pain. The results successfully demonstrated proof of concept for TRV130, and suggested potential differentiation from morphine. "The publication of these data in a leading pain research journal reflects the importance of our proof of concept bunionectomy study for TRV130," stated David Soergel, M.D., senior vice president, clinical and chief medical officer at Trevena. "This study provided us with important insights on the potential differentiation of TRV130 from morphine in a fixed dose setting, paving the way for the positive results from our recent Phase 2b trial of the candidate following abdominoplasty surgery. The abdominoplasty study utilized more clinically relevant on-demand dosing and showed better safety and tolerability for TRV130 than morphine with comparable levels of pain relief." The full publication is available at http://journals.lww.com/pain/toc/publishahead. About moderate-to-severe acute pain Mu opioid receptor agonists such as morphine and fentanyl are the most effective class of analgesics currently available and are the standard of care in moderate to severe acute pain; however, in published national surveys, a significant proportion of surgical patients have reported inadequate pain relief despite use of opioid analgesics. Opioid-related adverse effects such as respiratory depression, nausea and vomiting, are frequently dose-limiting, which complicates pain management and increases the burden of care.